Looking to list your PhD opportunities? Log in here.
This project is no longer listed on FindAPhD.com and may not be available.
Click here to search FindAPhD.com for PhD studentship opportunitiesAbout the Project
Background
Alternative RNA splicing is an extraordinary process that generates proteomic diversity (estimated at up to 150,000 human proteins) from only 20,000 human genes. More than 90% of human genes use splicing to produce on average multiple protein isoforms, sometimes with antagonistic functions, to be expressed from a single gene. However, mutations affecting splicing can result in the onset of disease such as cancer. A prominent example is the aberrant splicing of the Bcl-X gene which is an apoptotic checkpoint. Bcl-x pre-mRNA encodes two isoforms with antagonistic functions. The major protein isoform (Bcl-xL) displays anti-apoptotic functions and is overexpressed in most cancer cells. Overexpression of the alternative protein isoform (Bcl-xS) results in caspase-mediated apoptotic cell death.
We have recently identified a small molecule (GQC-05) which induces a switch in Bcl-X splicing towards the pro-apoptotic Bcl-xS pre-mRNA isoform. Whilst GQC-05 displays potent anti-cancer in live cells, the ability to delivery these safely and effectively in vivo is required for therapeutic applications.
Project objective
The overall objective of this collaborative PhD studentship is to develop synthetic methodology to prepare tumour targeting peptide conjugates of GQC-05 and next-generation analogues. This will involve the development of new synthetic methodology to establish structure-activity-relationship profiling of GQC-05 for G-quadruplex targets guided by our structural biology collaborator Professor Guang Zhu (Hong Kong University of Science & Technology)
The specific aims of the studentship are:
(i) Establish a structure-activity-relationship (SAR) profile of GQC-05 using a range of biophysical and biochemical assays and structural biological studies.
(ii) Optimise synthetic methodology to prepare tumour targeting conjugates of GQC-05.
(iii) Identify optimal candidates for analysis in live cells.
Academic Environments
The student will receive unparalleled training in medicinal chemistry and nucleic acid chemical biology based in Strathclyde. In addition, the student will have the opportunity to travel to HKUST and spend time in Professor Zhu’s research group and learn techniques ranging from structural biology (NMR and X-ray crystallography, Cryo-EM) through to conducting cell-based assays.
Funding Notes
References
2. Weldon. C.; Behm-Ansmant. I.; Hurley. L.H.; Burley. G.A.; Branlant. C.; Eperon. I.C.; Dominguez. C. "Specific G-quadruplex ligands modulate the alternative splicing of Bcl-X" Nucleic Acids Research, 2018, 46, 886.
3. Jobbins, A.M.; Reichenbach, L.F.; Lucas, C.M.; Hudson, A.J.; Burley. G.A.; Eperon. I.C. “The mechanisms of a mammalian splicing enhancer” Nucleic Acid Research, 2018, 46, 2145.
4. Weldon, C.; Behm-Ansmant, I.; Hurley, L.H.; Burley, G.A.; Branlant, C.; Eperon, I.C.; Dominguez, C. "Identification of G-quadruplexes in functional RNAs using FOLDeR" Nature Chemical Biology, 2016, 13, 18.
5. Geng, Y.; Liu, C.; Cai, Q.; Luo, Z.; Miao, H.; Shi, X.; Xu, N.; Fung, C. P.; Choy, T. T.; Yan, B.; Li, N.; Qian, P.; Zhou, B.; Zhu, G., Crystal structure of parallel G-quadruplex formed by the two-repeat ALS- and FTD-related GGGGCC sequence, Nucleic Acids Research 2021, 49, 5881.

Search suggestions
Based on your current searches we recommend the following search filters.
Check out our other PhDs in Glasgow, United Kingdom
Check out our other PhDs in United Kingdom
Start a New search with our database of over 4,000 PhDs

PhD suggestions
Based on your current search criteria we thought you might be interested in these.
Synthesis of New Anti-Cancer Agents and Pharmacogenomics of BRCA-mutated Cancers in the Qatar Population
Kingston University
Design, synthesis and evaluation of novel polysialyltransferase inhibitors as anti- metastatic agents
University of Bradford
Design, synthesis and evaluation of protease-activated anti-cancer prodrugs
University of Bradford